Sanctuary Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sanctuary Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9	Closed	-$786	–	266
2024 Q1	$786	Hold	9	–	–	﹤0.01%	246
2023 Q4	$868	Hold	9	–	–	﹤0.01%	253
2023 Q3	$796	Hold	9	–	–	﹤0.01%	245
2023 Q2	$780	Buy	+9	New	+$847	﹤0.01%	260
2022 Q4	$931	Buy	+9	New	+$845	﹤0.01%	239

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Sanctuary Wealth Management's BMRN Position: Q2 2024 in Review

Sanctuary Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 9 shares — an estimated $786 sold.

Sanctuary Wealth Management first reported a position in BMRN in Q4 2022 and held it in 5 quarters. The position peaked at $931 in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Sanctuary Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Sanctuary Wealth Management sold 9 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $786.
Sanctuary Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Sanctuary Wealth Management's BioMarin Pharmaceuticals position peaked at $931 in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Sanctuary Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.